胃炎Ⅰ号对慢性萎缩性胃炎癌前病变的干预作用
|
摘要
胃癌是消化道最常见的肿瘤之一,对胃癌早发现、早诊断、早治疗可明显提高其生存率。一般认为,胃粘膜上皮细胞在发展为恶性肿瘤之前,常经历多年持续的癌前病变,及早识别和治疗癌前病变是防治胃癌的有效途径。世界卫生组织胃癌专家会议指出慢性萎缩性胃炎(CAG)伴有不典型增生时是癌前病变。中药治疗慢性萎缩性胃炎癌前病变取得了较好的临床疗效,对于慢性萎缩性胃炎发病机理的研究正在逐渐深入到分子和基因水平。本课题运用分子生物学技术探讨中药胃炎Ⅰ号治疗慢性萎缩性胃炎的分子机制。
本文分为两个部分,第一部分文献研究主要总结了中医对慢性萎缩性胃炎病因病机的认识以及现代医学对慢性萎缩性胃炎癌前病变病因、发病机制、治疗方面的研究成果;第二部分实验研究,在成功复制慢性萎缩性胃炎动物模型的基础上,运用生化,放射免疫,明胶酶谱法,荧光定量PCR(SYBR Green)方法,研究慢性萎缩性胃炎自由基,炎症因子,金属基质蛋白酶2(MMP2)和金属基质蛋白酶抑制因子2(TIMP2)的活性,和表达的影响。
1.研究目的
观察胃炎Ⅰ号对慢性萎缩性胃炎癌前病变大鼠胃组织病理变化、自由基损伤、炎症因子,MMP-2及其抑制因子TIMP-2活性和RNA表达的影响。
通过观察慢性萎缩性胃炎癌前病变大鼠血清自由基损伤情况、炎症因子表达,胃组织MMP-2及其抑制因子TIMP-2活性和基因表达情况,及胃炎Ⅰ号的干预机制,以期揭示慢性萎缩性胃炎癌前病变的发病机制,并为胃炎Ⅰ号治疗慢性萎缩性胃炎癌前病变寻找新的靶点。
2.研究方法
60只SD大鼠,随机分为6组:模型组、空白阻、胃炎Ⅰ号方高、中、低剂量组和维酶素组,每组10只。除空白组只给生理盐水灌胃外,其余各组均采用甲基-硝基-亚硝基胍(MNNG)(1 g/L)和盐酸雷尼替丁胶囊(0.03 g/kg)灌胃建立慢性萎缩性胃炎模型,造模后各组均给予胃炎Ⅰ号(2.16g/kg·d;1.08g/kg·d;0.54g/kg·d)治疗90天。疗程结束后取血,分离出血清,使用生化方法测定过氧化物歧化酶(SOD),丙二醛(MDA)和含量,使用放射免疫法测定血清IL-1β、TNF-α含量。应用明胶酶谱法测定胃组织MMP2和TIMP2的活性,荧光定量PCR(SYBR Green)技术检测大鼠胃组织MMP-2,TIMP-2的mRNA表达水平,同时进行形态学观察。
3.研究结果
3.1.空白组的胃粘膜厚度正常,上皮细胞及腺体排列整齐。模型组出现明显的胃粘膜炎症、腺体萎缩及化生表现,未见明显的异型增生。胃炎Ⅰ号各治疗组与模型组比较有明显差异,表明胃炎Ⅰ号能有效的改善CAG的病理改变。
3.2.与模型组比较,胃炎Ⅰ号方3个治疗组血清SOD含量明显升高(P＜0.05),血清MDA的含量明显下降(P＜0.01),胃炎Ⅰ号各治疗组之间及胃炎Ⅰ号各组与维酶素组之间比较无统计学差异(P＞0.05)。
3.3.与空白组比较模型组血清IL-1β含量略升高,但没有统计学差异(P＞0.05)。与模型组比较各治疗组血清IL-1β含量略有降低,但没有统计学差异(P＞0.05)。
与空白组比较各组大鼠血清TNF-α含量均有不同程度升高,但只有模型组有显著差异(P＜0.05)。与模型组比较,给予胃炎Ⅰ号方中,低剂量组和维酶素组血清TNF-α含量明显降低,而胃炎Ⅰ号高剂量组TNF-α含量降低不明显。
3.4.与空白组比较各组大鼠胃粘膜MMP-2活性均有不同程度升高,以模型组最为明显(P＜0.05)。与模型组比较,给予胃炎Ⅰ号各组和维酶素组MMP-2活性明显降低(P＜0.05),而胃炎Ⅰ号中剂量组MMP-2活性降低最明显。
与空白组比较各组胃粘膜TIMP-2活性均有不同程度下降但只有模型组有显著差异(P＜0.05)。与模型组比较,给予胃炎Ⅰ号方各组和维酶素组胃组织TIMP-2活性明显升高(P＜0.05),其中胃炎Ⅰ号中剂量组升高最明显,优于维酶素组。
3.5.造模后各组大鼠胃粘膜MMP-2 RNA的表达均有不同程度升高。给予胃炎Ⅰ号和维酶素后,治疗组MMP-2RNA的表达明显降低,其中胃炎Ⅰ号中剂量组效果最佳。
造模后各组大鼠胃粘膜TIMP-2 RNA的表达均有不同程度降低于空白组。与模型组比较给予胃炎Ⅰ号方各治疗组和维酶素组胃粘膜TIMP-2RNA的表达有升高趋势,但没有统计学差异(P＞0.05)。
4.结论
4.1胃炎Ⅰ号能改善实验性慢性萎缩性胃炎大鼠的胃粘膜病理改变。
4.2胃炎Ⅰ号能通过升高血清SOD含量、降低血清MDA含量来减少慢性萎缩性胃炎大鼠的自由基损伤的作用。
4.3胃炎Ⅰ号能减少炎症因子TNF-α含量。
4.4慢性萎缩性胃炎大鼠胃组织中MMP2的活性升高而TIMP-2活性降低损伤因素增加而保护因素降低,所以有增加癌前病变损伤。
胃炎Ⅰ号各组和维酶素组可降低MMP-2活性,增加TIMP-2活性从而达到降低慢性萎缩性胃炎的癌前病变的作用。
Gastric carcinoma is one of the most common tumors.It early detection, diagnosis,and treatment will greatly decrease mortality rate.There is a long time period of precancerous change before the normal mucosa change into carcinoma.Detecting and treating precancerous lesions is a good way to prevent gastric carcinoma.WHO experts indicated that Chronic atrophic gastritis with dysplasia is a precancerous lesion.Traditional chinese medicine has good curative effects on it.
My thesis can be divided into two parts.In the part 1,I summarized the cognition of cause and mechanisms of chronic atrophic gastritis in the view of traditional chinese medicine,and review progress of its etiological factors,pathogenesis,treatment of western and traditional medicine.In the part 2,based on replicating animal model of chronic atrophic gastritis,using biochemical,radioimmunoassay,western blott and PCR technique to study effects of Weiyanyihao formula on freeradical,inflammatory factors, activities and expression of MMPZ and TIMP2.
1.Purpose
To study effects of Weiyan yihao formula on histopathological changes, freeradical damage,inflammatory factors,activities and expression of MMP2 and its inhibitor TIMP-2 of gastric tissues in chronic atrophic rats with precancerous lesions.
Observating serum free radical damage,the expression of inflammatory cytokines,gastric tissue MMP-2 and its inhibitor TIMP-2 activity and gene expression in rats with chronic atrophic gastritis precancerous lesions and intervention mechanism of Weiyanyihao,with a view to reveal pathogenesis of precancerous lesions in chronic atrophic gastritis,as so as treatment effects of Weiyanyihao on chronic atrophic gastritis precancerous lesions to find a new target.
2.Method
60 SD rats were radomisely devided into 6 groups:(10 animals in each): model group,control group,Weiyanyihao with high-dose,medium-dose and low-dose group and Weimeisu group.Except the control group received intragastrical administration of normal saline,the rest five groups underwent intragastric MNNG and ranitidine hydrochloride capsules administration to be made into CAG models.Afterwards,corresponding medication was administered to each group for 90 days.After the end of treatment,isolating from the serum, using biochemical method to measure SOD and MDA content,using of radioimmunoassay to measure Serum IL-1β,TNF-αcontent;morphological observation at the same time.Using Western blot to measure activity of MMP2 and TIMP2 in gastric tissue,using PCR technic(SYBR Green) to detecte levels of mRNA MMP-2,TIMP-2 expression in rat gastric tissue.
3.Results
3.1.The model group has significant stomach membrane inflammation,gland atrophy and metaplasia.There is no significant dysplasia.There are significant differences between Weiyanyihao groups and model group.It indicated that Weiyanyihao formula has improvement effect on the pathological changes in CAG。
3.2.Compared to the model group,that of SOD level in the three Wei yanyihao groups significantly higher while the contents of MDA is significantly lower,and the difference was statistically significant.But, there was no statistical difference between Weiyanyihao groups and Weimeisu group.
3.3.Compared with the control group,serum IL-1βconcentration slightly increased but there is no statistical difference.Compared with the model group,in the treatment group the serum IL-1βcontent is slight decrease but no statistical difference.
Compared with control group,serum TNF-αcontent in treatment groups were increased,but only the model group had significantly different.Compared with model group,serum TNF-αin Weiyanyihao with middle and low-dose groups and Weimeisu group were significantly lower,and in Weiyanyihao with high dose group TNF-αwas decreased not obviously.
3.4.Compared with control group,MMP-2 activity in all rats groups were increased in varying degrees but only in model group the increase was most obvious.Compared with model group,treatment with Weiyanyihao and Weimeisu groups MMP-2 activity was significantly lower,and Weiyan yihao with middle dose had the best effect.
Compared with the control group,TIMP-2 activity in all groups were decreased in varying degrees but only the model group were significantly different.Compared with the model group,treatment with Weiyanyihao and Weimeisu,TIMP-2 activity was significantly increased,Weiyanyihao with middle dose had the best effect.
3.5.In chronic atrophic model rats,MMP-2 RNA expression increased.After treatment with Weiyanyihao and Weimeisu,the expression of MMP-2RNA significantly decreased,Weiyanyihao with middle dose had the best effect.
In chronic atrophic model rats,TIMP-2 RNA expression of gastrictissue was reduced.After treatment with Weiyanyihao and Weimeisu,the expression of TIMP-2RNA trend to be increased,but there was no statistical difference.
4.Conclusion
4.1.Weiyanyihao can improve pathological changes of of experimental chronic atrophic gastritis in rats.
4.2.It is suggested that Weiyanyihao can increase the level of serum SOD,decrease the content of serum MDA,which maybe contribute to treatment effect on chronic atrophic gastritis rats.
4.3.Weiyanyihao can reduce the inflammatory cytokines TNF-αcontent.
4.4.In gastric tissue of rat chronic atrophic gastritis activity of MMP2 is increased and activity of TIMP-2 is reduced,so injury factors are increased and protective factors are reduced,so it increase precancerous lesions.
Weiyanyihao and Weimeisu can reduce MMP-2 activity,while increase TIMP-2 activity,so they can reduce the the possibility of gastric precancerous lesions.
本文分为两个部分,第一部分文献研究主要总结了中医对慢性萎缩性胃炎病因病机的认识以及现代医学对慢性萎缩性胃炎癌前病变病因、发病机制、治疗方面的研究成果;第二部分实验研究,在成功复制慢性萎缩性胃炎动物模型的基础上,运用生化,放射免疫,明胶酶谱法,荧光定量PCR(SYBR Green)方法,研究慢性萎缩性胃炎自由基,炎症因子,金属基质蛋白酶2(MMP2)和金属基质蛋白酶抑制因子2(TIMP2)的活性,和表达的影响。
1.研究目的
观察胃炎Ⅰ号对慢性萎缩性胃炎癌前病变大鼠胃组织病理变化、自由基损伤、炎症因子,MMP-2及其抑制因子TIMP-2活性和RNA表达的影响。
通过观察慢性萎缩性胃炎癌前病变大鼠血清自由基损伤情况、炎症因子表达,胃组织MMP-2及其抑制因子TIMP-2活性和基因表达情况,及胃炎Ⅰ号的干预机制,以期揭示慢性萎缩性胃炎癌前病变的发病机制,并为胃炎Ⅰ号治疗慢性萎缩性胃炎癌前病变寻找新的靶点。
2.研究方法
60只SD大鼠,随机分为6组:模型组、空白阻、胃炎Ⅰ号方高、中、低剂量组和维酶素组,每组10只。除空白组只给生理盐水灌胃外,其余各组均采用甲基-硝基-亚硝基胍(MNNG)(1 g/L)和盐酸雷尼替丁胶囊(0.03 g/kg)灌胃建立慢性萎缩性胃炎模型,造模后各组均给予胃炎Ⅰ号(2.16g/kg·d;1.08g/kg·d;0.54g/kg·d)治疗90天。疗程结束后取血,分离出血清,使用生化方法测定过氧化物歧化酶(SOD),丙二醛(MDA)和含量,使用放射免疫法测定血清IL-1β、TNF-α含量。应用明胶酶谱法测定胃组织MMP2和TIMP2的活性,荧光定量PCR(SYBR Green)技术检测大鼠胃组织MMP-2,TIMP-2的mRNA表达水平,同时进行形态学观察。
3.研究结果
3.1.空白组的胃粘膜厚度正常,上皮细胞及腺体排列整齐。模型组出现明显的胃粘膜炎症、腺体萎缩及化生表现,未见明显的异型增生。胃炎Ⅰ号各治疗组与模型组比较有明显差异,表明胃炎Ⅰ号能有效的改善CAG的病理改变。
3.2.与模型组比较,胃炎Ⅰ号方3个治疗组血清SOD含量明显升高(P＜0.05),血清MDA的含量明显下降(P＜0.01),胃炎Ⅰ号各治疗组之间及胃炎Ⅰ号各组与维酶素组之间比较无统计学差异(P＞0.05)。
3.3.与空白组比较模型组血清IL-1β含量略升高,但没有统计学差异(P＞0.05)。与模型组比较各治疗组血清IL-1β含量略有降低,但没有统计学差异(P＞0.05)。
与空白组比较各组大鼠血清TNF-α含量均有不同程度升高,但只有模型组有显著差异(P＜0.05)。与模型组比较,给予胃炎Ⅰ号方中,低剂量组和维酶素组血清TNF-α含量明显降低,而胃炎Ⅰ号高剂量组TNF-α含量降低不明显。
3.4.与空白组比较各组大鼠胃粘膜MMP-2活性均有不同程度升高,以模型组最为明显(P＜0.05)。与模型组比较,给予胃炎Ⅰ号各组和维酶素组MMP-2活性明显降低(P＜0.05),而胃炎Ⅰ号中剂量组MMP-2活性降低最明显。
与空白组比较各组胃粘膜TIMP-2活性均有不同程度下降但只有模型组有显著差异(P＜0.05)。与模型组比较,给予胃炎Ⅰ号方各组和维酶素组胃组织TIMP-2活性明显升高(P＜0.05),其中胃炎Ⅰ号中剂量组升高最明显,优于维酶素组。
3.5.造模后各组大鼠胃粘膜MMP-2 RNA的表达均有不同程度升高。给予胃炎Ⅰ号和维酶素后,治疗组MMP-2RNA的表达明显降低,其中胃炎Ⅰ号中剂量组效果最佳。
造模后各组大鼠胃粘膜TIMP-2 RNA的表达均有不同程度降低于空白组。与模型组比较给予胃炎Ⅰ号方各治疗组和维酶素组胃粘膜TIMP-2RNA的表达有升高趋势,但没有统计学差异(P＞0.05)。
4.结论
4.1胃炎Ⅰ号能改善实验性慢性萎缩性胃炎大鼠的胃粘膜病理改变。
4.2胃炎Ⅰ号能通过升高血清SOD含量、降低血清MDA含量来减少慢性萎缩性胃炎大鼠的自由基损伤的作用。
4.3胃炎Ⅰ号能减少炎症因子TNF-α含量。
4.4慢性萎缩性胃炎大鼠胃组织中MMP2的活性升高而TIMP-2活性降低损伤因素增加而保护因素降低,所以有增加癌前病变损伤。
胃炎Ⅰ号各组和维酶素组可降低MMP-2活性,增加TIMP-2活性从而达到降低慢性萎缩性胃炎的癌前病变的作用。
Gastric carcinoma is one of the most common tumors.It early detection, diagnosis,and treatment will greatly decrease mortality rate.There is a long time period of precancerous change before the normal mucosa change into carcinoma.Detecting and treating precancerous lesions is a good way to prevent gastric carcinoma.WHO experts indicated that Chronic atrophic gastritis with dysplasia is a precancerous lesion.Traditional chinese medicine has good curative effects on it.
My thesis can be divided into two parts.In the part 1,I summarized the cognition of cause and mechanisms of chronic atrophic gastritis in the view of traditional chinese medicine,and review progress of its etiological factors,pathogenesis,treatment of western and traditional medicine.In the part 2,based on replicating animal model of chronic atrophic gastritis,using biochemical,radioimmunoassay,western blott and PCR technique to study effects of Weiyanyihao formula on freeradical,inflammatory factors, activities and expression of MMPZ and TIMP2.
1.Purpose
To study effects of Weiyan yihao formula on histopathological changes, freeradical damage,inflammatory factors,activities and expression of MMP2 and its inhibitor TIMP-2 of gastric tissues in chronic atrophic rats with precancerous lesions.
Observating serum free radical damage,the expression of inflammatory cytokines,gastric tissue MMP-2 and its inhibitor TIMP-2 activity and gene expression in rats with chronic atrophic gastritis precancerous lesions and intervention mechanism of Weiyanyihao,with a view to reveal pathogenesis of precancerous lesions in chronic atrophic gastritis,as so as treatment effects of Weiyanyihao on chronic atrophic gastritis precancerous lesions to find a new target.
2.Method
60 SD rats were radomisely devided into 6 groups:(10 animals in each): model group,control group,Weiyanyihao with high-dose,medium-dose and low-dose group and Weimeisu group.Except the control group received intragastrical administration of normal saline,the rest five groups underwent intragastric MNNG and ranitidine hydrochloride capsules administration to be made into CAG models.Afterwards,corresponding medication was administered to each group for 90 days.After the end of treatment,isolating from the serum, using biochemical method to measure SOD and MDA content,using of radioimmunoassay to measure Serum IL-1β,TNF-αcontent;morphological observation at the same time.Using Western blot to measure activity of MMP2 and TIMP2 in gastric tissue,using PCR technic(SYBR Green) to detecte levels of mRNA MMP-2,TIMP-2 expression in rat gastric tissue.
3.Results
3.1.The model group has significant stomach membrane inflammation,gland atrophy and metaplasia.There is no significant dysplasia.There are significant differences between Weiyanyihao groups and model group.It indicated that Weiyanyihao formula has improvement effect on the pathological changes in CAG。
3.2.Compared to the model group,that of SOD level in the three Wei yanyihao groups significantly higher while the contents of MDA is significantly lower,and the difference was statistically significant.But, there was no statistical difference between Weiyanyihao groups and Weimeisu group.
3.3.Compared with the control group,serum IL-1βconcentration slightly increased but there is no statistical difference.Compared with the model group,in the treatment group the serum IL-1βcontent is slight decrease but no statistical difference.
Compared with control group,serum TNF-αcontent in treatment groups were increased,but only the model group had significantly different.Compared with model group,serum TNF-αin Weiyanyihao with middle and low-dose groups and Weimeisu group were significantly lower,and in Weiyanyihao with high dose group TNF-αwas decreased not obviously.
3.4.Compared with control group,MMP-2 activity in all rats groups were increased in varying degrees but only in model group the increase was most obvious.Compared with model group,treatment with Weiyanyihao and Weimeisu groups MMP-2 activity was significantly lower,and Weiyan yihao with middle dose had the best effect.
Compared with the control group,TIMP-2 activity in all groups were decreased in varying degrees but only the model group were significantly different.Compared with the model group,treatment with Weiyanyihao and Weimeisu,TIMP-2 activity was significantly increased,Weiyanyihao with middle dose had the best effect.
3.5.In chronic atrophic model rats,MMP-2 RNA expression increased.After treatment with Weiyanyihao and Weimeisu,the expression of MMP-2RNA significantly decreased,Weiyanyihao with middle dose had the best effect.
In chronic atrophic model rats,TIMP-2 RNA expression of gastrictissue was reduced.After treatment with Weiyanyihao and Weimeisu,the expression of TIMP-2RNA trend to be increased,but there was no statistical difference.
4.Conclusion
4.1.Weiyanyihao can improve pathological changes of of experimental chronic atrophic gastritis in rats.
4.2.It is suggested that Weiyanyihao can increase the level of serum SOD,decrease the content of serum MDA,which maybe contribute to treatment effect on chronic atrophic gastritis rats.
4.3.Weiyanyihao can reduce the inflammatory cytokines TNF-αcontent.
4.4.In gastric tissue of rat chronic atrophic gastritis activity of MMP2 is increased and activity of TIMP-2 is reduced,so injury factors are increased and protective factors are reduced,so it increase precancerous lesions.
Weiyanyihao and Weimeisu can reduce MMP-2 activity,while increase TIMP-2 activity,so they can reduce the the possibility of gastric precancerous lesions.
引文
[1]Dinis-Ribeiro M,Lopes C,da Costa-Pereira A,Guilherme M,Barbosa J,Lomba-Viana H,Silva R,Moreira-Dias L.A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia.J Clin Pathol,2004 Feb;57(2):177-8.
[2]危北海.慢性萎缩性胃炎的临床研究.陕西中医,1987,8(7):296.
[3]周惠萌,范欣敏.上消化道疾病9910例胃镜检查结果分析.中国中西医结合消化杂志,2003,11(3):167-168.
[4]孟静岩主编.慢性萎缩性胃炎.北京:中国医药科技出版社,2003(8):42.
[5]王永炎主编.中西内科学.上海科技出版社,2002:169.
[6]张聪,陈明.自拟舒胃汤治疗慢性萎缩性胃炎36例[J].辽宁中医学院学报,2004,6(5):381.
[7]祁宏,耿曙光,许定仁,等.萎胃康治疗慢性萎缩性胃炎的疗效及对血液流变学的影响[J].中国中西医结合急救杂志,2004;11(1):42-44.
[8]王钢,常建国,刘红玉.养阴活血法治疗慢性萎缩性胃炎84例.陕西中医,2004;25(1):4.
[9]代二庆:赵占考,袁红霞,等.善胃Ⅰ-Ⅲ号方治疗慢性萎缩性胃炎胃癌前病变的临床研究.中医药学刊,2004;22(4):606.
[10]赵霞.余绍源教授辨治慢性萎缩性胃炎经验.四川中医,2004,22(4):1.
[11]周建莉.胃复春治疗萎缩性胃炎112例[J].实用中医药杂志,2004;20(6):316.
[12]劳绍贤.慢性萎缩性胃炎的临床研究.陕西中医,1987,8(7):289.
[13]项翠华.慢性萎缩性胃炎的病因病机探讨.新疆中医药,2000,18(3):7.
[14]王汝新,牛华珍.温阳补肾活血法治疗慢性萎缩性胃炎180例观察.实用中医药杂志,2000,16(11):11.
[15]刘启泉,杨翠香,肖彦玲等.慢性萎缩性胃炎的中医病机研究.河北中医,2002,24(6):473-475.
[16]危北海,张万岱,陈治水主编.中西医结合消化病学.北京:人民卫生出版社,2003(5):553.
[17]王金荣,王知佳.中医辨证治疗慢性萎缩性胃炎52例[J].中西医结合学报,2004;2(1):65.
[18]高富贵.慢性萎缩性胃炎中医辨证治疗108例.医学理论与实践,2004;17(8):908-909.
[19]张宁.辨证分型治疗慢性萎缩性胃炎128例[J].湖南中医杂志,2004,20(3):4.
[20]任宏义.辨证论治150例慢性萎缩性胃炎的病理形态血观察.中国中西医结合杂志,1993,13(3):144.
[21]柯莹玲,单兆伟.542例慢性萎缩性胃炎患者中医辨证分型与病因分析.辽宁中医杂志,2006,33(2):161-162.
[22]袁福宁.辨证论治慢性萎缩性胃炎50例.光明中医,2006,21(4):59.
[23]王绪霖,潘从清,孙保存.344例慢性萎缩性胃炎患者的辨证分型分析,1999,14、5(1):90-91.
[24]蒋兴伟.李任先教授治疗胃病经验.新中医,1997;29(3):10-11.
[25]刘西峰,白丽萍,米新.辨证治疗慢性萎缩性胃炎96例.陕西中医2004,25(1):8.
[26]魏道祥.辨证分型治疗慢性萎缩性胃炎1276例.山东中医杂志,2003,22(11):673-674.
[27]吴治恒,杨玲,段其昌.和胃调气养血汤加减治疗萎缩性胃炎临床观察.中国民族民间医药杂志,2006,78:38-40.
[28]陈一斌.益胃方治疗慢性萎缩性胃炎60例.河南中医,2006,26(3):34-35.
[29]邓照华.益气健脾汤治疗慢性萎缩性胃炎33例.中国中西医结合消化杂志,2006,14(2):133-134.
[30]潘星宇,王小宁.资生丸治疗慢性萎缩性胃炎110例体会.CJTCM Feb.2006 Vol.18 No.1:68.
[31]李小兵,周红霞.愈胃颗粒治疗慢性萎缩性胃炎128例临床观察. 河南中医,2004,24(3):35.
[32]郑于星.胃炎宁胶囊治疗萎缩性胃炎·临床观察。 Strait Pharmaceutical Journal Vol 19 No.4-2007,83-84.
[33]陈德成,吴旭.穴位注射治疗慢性萎缩性胃炎疗效观察.中国乡村医生杂志,2000年第八期40.
[34]谭奇纹.针刺夹脊穴治疗慢性萎缩性胃炎临床研究.中国针灸,2000年第3期331.
[35]谢文松.药灸并用治疗慢性萎缩性胃炎46例.河北中医,2000第22卷619.
[36]Gao X,Yuan J,Li H,Ren S.Clinical research on acupuncture and moxibustion treatment of chronic atrophic gastritis.J Tradit Chin Med,2007 3un;27(2):87-91.
[37]Gao X,Rao H,Wang Y,Meng D,Wei Y.Protectiveaction of acupuncture and moxibustion on gastric mucosa in model rats with chronic atrophic gastritis.J Tradit Chin Med,2005 Mar;25(1):66-9.
[38]李伟,陈颖莉,杨铭等.胃乐优对胃粘膜损伤的保护作用.中药药理。与临床,1995,11(1):391.
[39]霍本运,许嘉民,王钡礼。胃康泰的药理作用.中成药,1995,13(3):301.
[40]邓兰琼,崔世高,刘喜明,等.柴胡桂枝汤对大鼠胃粘膜保护作用的实验研究.中国中西医结合脾胃杂志,1998,6(3):1641.
[41]徐州,周德瑞,段国勋等.中药对幽门螺杆菌抑制作用的实验研究.中国医药学报,1993;8(5):25-26.
[42]王绪霖,缴稳玲,吕宗舜.抑制幽门螺杆菌中药的初步筛选.中国中西医结合杂志,1994:9(14):534.
[43]苟奎斌,王荣华,孙丽华.中药对幽门螺杆菌的抑菌试验.中国药学杂志,1994;29(9):554.
[44]徐艺,叶柏,单兆伟等.中草药单味与复方对幽门螺杆菌抑菌作用研究.中国中西医结合脾胃志,2000;5(8):292-293.
[45]冀爱英,赵文霞,王智慧等.夏连抑幽胶囊治疗幽门螺杆菌感染性 胃炎的临床及实验研究.中国中西医结合杂志,1999;19(10):595-598.
[46]李振彬,万建喜.和平散对消炎痛致大鼠胃粘膜损伤的保护作用.中国医师杂志,2002;4(10):1108.
[47]张大振,万建喜.胃痛灵汤对胃粘膜保护作用的时间节律研究.河北中医,2002;24(12):956.
[48]王晶,侯家玉,刘衡宽等.胃舒颗粒对胃粘膜保护作用的实验研究.北京中医药大学学报,1999;22(2):59-62.
[49]洪缨,孟紫芊,侯家玉等.小柴胡汤、香砂六君子汤对胃粘膜保护作用的实验研究.北京中医药大学学报,1994;17(5):57-59.
[50].王汝俊,傅定中,邵庭萌.补中益气汤的药理作用研究——抗胃粘膜损伤作用与机理.中药药理与临床,1993(2):5-7.
[51]洪缨,侯家玉,朱洪滨等.小柴胡汤及香砂六君子汤对胃粘液-碳酸氢盐屏障功能影响的实验研究.中药药理与临床,1994;(6):3-5.
[52]刘良,王建华,侯宁等.党参及其有效成分抗胃粘膜损伤作用与机制研究——党参提取物Ⅶ～Ⅱ对胃组织内前列腺素含量的影响.中药药理与临床,1990;6(3):9-11.
[53]李桂,蒋福斌,王建增等.胃康胶囊对消炎痛诱导大鼠胃粘膜损伤血液中相关细胞因子含量的影响.中国中西医结合消化杂志,2003;11(1):33-35.
[54]周兰,孙桂华,宋鸿.中药养胃散对消炎痛损伤的大白鼠胃粘膜的保护作用.广州医药,2001;32(6):9-10.
[55]王长洪,王艳红,周莹等.中药对胃粘膜合成前列腺素的临床及实验研究.中国中西医结合杂志,1994;14(9):528-530.
[56]王付,尚炽昌,梁华龙等.加味黄连汤对大鼠实验性胃粘膜损伤的影响及病理组织学改变.中国中医药信息杂志,2000;7(3):34-35.
[57]徐颖,张祖志,万正清,等.半夏泻心汤对应激性胃粘膜损伤大鼠血管活性肠肽含量的影响.中医药临床杂志,2004;16(2):97.
[58]程村贵,洪洁,王钦茂等.胃泰胶囊的临床药效学研究.医学信息,2002;15(1):71.
[59]姚永莉,宋于刚,张万岱.四君子汤治疗实验脾虚证对胃肠黏膜细 胞增殖动力学的影响.世界华人消化杂志,1999;7:550.
[60]张永锋,王建华,王汝俊.补中益气汤的药理作用研究——抗胃黏膜损伤机理探讨.中药药理与临床,1992;8:1-3.
[61]向爱民,周德端,徐州等.香砂六君合剂对大鼠胃黏膜屏障的保护作用.世界华人消化杂志,1999;7:600.
[62]谢海青,尹昌金,熊磊.香砂六君子汤抗大鼠胃粘膜损伤并脾气虚症实验研究.云南中医学院学报,1992;15(3):15-17.
[63]Namekata T,Miki K,Kimmey M,Fritsche T,Hughes D,Moore D,Suzuki K.Chronic atrophic gastritis and Helicobacter pylori infection among Japanese Americans in Seattle.Am J Epidemiol,2000 Apr 15;151(8):820-30.
[64]Weck MN,Brenner H.Association of Helicobacter pylori infection with chronic atrophic gastritis:Meta-analyses according to type of disease definition.Int J Cancer.2008 Aug 15;123(4):874-81.
[65]Brenner H,Rothenbacher D,Weck MN.Epidemiologic findings on serologically defined chronic atrophic gastritis strongly depend on the choice of the cutoff-value.Int J Cancer,2007 Dec 15;121(12):2782-6.
[66]Weck MN,Stegmaier C,Rothenbacher D,Brenner H.Epidemiology of chronic atrophic gastritis:population-based study among 9444 older adults from Germany.Aliment Pharmacol Ther,2007 Sep 15;26(6):879-87.
[67]马汴梁主编.食管胃肠病中西医结合诊治.北京:人民卫生出版社,2003(8)122-125.
[68]Warren JR and Marshall BJ.Unidentified curved bacillion gastric epithelium active chronic gastritis.Lancet,1983,I:1273-1275.
[69]Kuipers EJ,Uyterlinde AM,Pena AS,et al.Long term sequelae of Helicobacter pylori gastritis.Lancet,1995,345:1525-1528.
[70]Keates AC,Tummala S,Peek RM Jr,Csizmadia E,Kunzli B,Becker K,Correa P,Romero-Gallo J,Piazuelo MB,Sheth S,Kelly CP,Robson SC, Keates S.Helicobacter pylori infection stimulates plasminogen activator inhibitor 1 production by gastric epithelial cells.Infect Immun.2008 Sep;76(9):3992-9.Epub 2008 Jun 2.
[71]Lee YC,Lin JT,Chen TH,Wu MS.Is Eradication of Helicobacter pylori the Feasible Way to Prevent Gastric Cancer? New Evidence and Progress,but Still a Long Way to Go.J Formos Med Assoc.2008Aug;107(8):591-9.
[72]Goldstein NS,Lewin KJ.Gastric epithelial dysplasia and adenoma:historical review and histological criteria for grading.Hum Pathol,1997;28(2):127-133.
[73]Mclord JM.The superoxide free radical:Its biochemistry and pathophysiology.Surgery,1983;9:412-416.
[74]Parks D.Oxygen radicals:mediators of gastrointestinal pathophysiology.Gut,1989;30:293-294.
[75]陈瑗,周玫.自由基医学.第1版.北京:人民军医出版社,1991:4-7.
[76]De Flora S.Antioxidant activity and other mechanisms of thiols involved in chemoprevention of mutation and cancer.Ann J Med,1991;91(Suppl 3C):122-130.
[77]Sandy MS,Dimoute D,Smith MJ.Relationships between intracellular vitamin E,lipid peroxidation and chemical toxicity in hepatocytes.Tokicol Appl Pharmacol,1988;93(1):288-297.
[78]Prise KM,Davies S,Stratford MRL,Michael BD.The role of non protein salphydryls in determining the chemical repair rats of free radical precursors of DNA damage and cell killing in Chinese hamster V 79 cells.Int J Radiat Biol,1992;62(3):297-306.
[79]张玉.慢性萎缩性胃炎胃粘膜血流量的研究.中华消化内镜杂志,1997,14(2):101.
[80]张维颖.慢性萎缩性胃炎患者血液流性学及甲襞微循环变化的研究观察150例微循环杂志.1997,7(1):40.
[81]张旭晨,赵凤志,宋崇顺,等.消痞灵冲剂对实验性胃癌前期病变大鼠血液流变学的影响。新消化病学杂志,1996,4:208-210.
[82]Owen RJ,Hurtado A,Banatvala N,Abdi Y,Davies GR,Feldman R,Hardie JM.Conservation of cytotoxin-associated(cagA) gene of Helicobacter pylori and investigaion of association with vacuolating cytotoxin activity and gastroduodenal disease.FEMS Immun Med Microbiol,1994;9:307-316.
[83]Xiang Z,Censini S,Bayeli PF,et al.Analysis of expression of Cag A and VacA virulence factors in strains of Helicobacterpylori that clinical isolate scan be divided into major types and that Cag A is not necessary for expression of the vacuolating cytotoxin.Infect Immun,1995,63(1):94 98.
[84]Peek RM Jr,MossSF,Tham KT,Perez-Perez GI,Wang S,Miller GG,Atherton JC,Holt PR,Blaser MJ.Helicobacter pylori cagA+strains and dissociation of gastric epithelial cell proliferation from apoptosis.J Natl Cancer Inst,1997;89:863-868.
[85]Vanderberg FM,Mans MZ,Langenberg W,et al.detection of Campylobacterpylori in stomach tissue by DNA insitu hybridization,J clin Pathol,1989;42:955.
[86]熊碧芳,方向明,刘小红,等.幽门螺杆菌细胞毒素相关基因A 与胃癌发生的临床研究.中国内镜杂志,2001(7):4:43.
[87]Romaozinho JM,Souto P,Rodrigues VL,et al.Seroprevalence of comtibodies to CagA and VacA proteins resus gastric cancer risk,Gut 1996;39(S2):A81.
[88]Giannakis M,Chen SL,Karam SM,Engstrand L,Gordon JI.Helicobacter pylori evolution during progression from chronic atrophic gastritis to gastric cancer and its impact on gastric stem cells.Proc Natl Acad Sci U S A.2008 Mar 18;105(11):4358-63.Epub 2008 Mar.
[89]杨金禄.慢性萎缩性胃炎幽门螺杆菌感染量与一氧化氮、脂质过氧化物的变化.医师进修杂志,1997,20(5):250.
[90]韩梅娇,金晓明,牟海滨,等.慢性萎缩性胃炎与幽门螺杆菌cagA、vacA基因相关性研究.哈尔滨医科大学学报,2003年12月第37卷第6期497.
[91]Won Chang Y,Oh HC,Young Jang J,Hwangbo Y,Won Lee J,Jung Lee H,Ro Joo K,Ho Dong S,Soo Kim S,Jong Kim H,Ho Kim B,Chang R.IL-lbeta and IL-8,matrix metalloproteinase 3,and pepsinogen secretion before and after H.pylori eradication in gastroduodenal phenotypes.Scand J Gastroenterol.2008 May 19:1-10.
[92]Greene J,Wang M,Liu YE,Raymond LA,Rosen C,Shi YE.Molecular cloning and characterization of human tissue inhibitor of metalloproteinase-4.J Biol Chem,1996,271(48):30375-30380.
[93]李平安,于美丽。MMP2、TIMP2与胃癌淋巴结转移关系的探讨。中国医学杂志,2004,2(5):241-243.
[94]钟华,徐灿霞,文锋。MMP2、TIMP2与胃癌淋巴结转移关系的探讨。中国医学杂志,2004,2(5):241-243.
[95]Brew K,Dinakarpandian D,Nagase H.Tissue inhibitors of metalloproteinases:evolution,structure and funtion.Biochem Biophys Acta,2000,1477(1-2):267-283.
[96]Olga F.,Manish Kh.and Bruce R S.Metalloproteinase-2expression correlates with aggressiveness of cutaneous squamous cell carcinomas.Modern Pathology,2004.17:496-502.
[97]He Qing,Chen Jie,Lin Han-liang.Expression of peroxisome proliferator-activated receptor g,E-cadherin and matrix metalloproteinases-2 in gastric carcinoma and lymph node metastases.Chinese Medical Journal,2007,120(17):1498-1504.
[98]Lamoreaux WJ,Fitzgerakd M,Reiner A,et al.Vascular endothelial growthfactor increases releases of gelatinase A and decreases release of tissue inhibition of metalloprotainase by microvascular endothelial cells in vitro[J].Microvas Res,1998,55:29.
[99]栾复新,王孟薇.环氧化酶22和基质金属蛋白酶27在老年胃癌组 织中表达及预后意义.军医进修学院学报.2005,25(6):28-29.
[100]李春启,刘为纹,房殿春.实验动物胃粘膜癌前病变的模型建立,发生机理及其逆转治疗的研究.第三军医大学学报,1994;16:5-9.
[101]杨云,陈小野,郭育芝.劳倦和饥饱失常引起的大鼠脾虚证模型的造型及实验研究.中国医药学报,1989;4:65-67.
[102]陈小野,邹世洁.大鼠CAG证病结合模型的造模方法和思路.实验动物科学与管理,2002(19)3:3538.
[103]Si J,Zhou W,Wu J,Cao Q,Xiang Z,Jiang L,L(u|¨) W,Huang H.Establishment of an animal model of chronic atrophic gast.ritis and a study on the factors inducing atrophy.Chin Med J(Engl).2001Dec;114(12):1323-5.
[104]Lee A.A small animal model of human helicobat pylori actine chronic gastritis.GastroenterologY,1990,99:1315.
[105]Fox J G.Helico bacter mustelae-associated gastritis in fernes:ananimal model of helicobacter pylori gastritis in humans.Gastroenterology,1990,99:352.
[106]朱方石.中医药对萎缩性胃炎动物模型研究进展与评述.上海中医药大学学报,2003,17(3):61-64.
[107]赵凤志.人鼠实验性慢性萎缩性胃炎形态研究.北京中医学院学术资料汇编,1989.79.
[108]高碧珍,黄爱民,李灿东,等.不同证候胃炎模型血生化指标的实验研究.福建中医学院学报,2005,15(1):30-32.
[109]Iacopini F,Consolazio A,Bosco D.Oxidative damage of the gastric mucosa in Helicobacter pylori positive chronic atrophic and nonatrophic gastritis,before and after eradication[J].Helicobacter,2003,8(5):503-12.
[110]Sasazuki S,Hayashi T,Nakachi K,Sasaki S,Tsubono Y,Okubo S,Hayashi M,Tsugane S.Protective effect of vitamin C on oxidative stress:a randomized controlled trial[J].Int J Vitam Nutr Res,2008,78(3):121-8.
[111]梁实,月中瘤坏死的另一面,促进某些白血病细胞生长作用,国外医学肿瘤学分册1994,21(6):334。
[112]骆和生,罗鼎辉,主编.免疫中药学.北京:北京医科大学,中国协和医科大学联合出版社出版,1990:97-99.
[113]杨贵贞,等.甘草多糖的体内外免疫效应.中西医结合杂志1988,(基础理论研究特辑),107.
[114]Monig SP,Baldus SE,Hennecken JK,Spiecker DB,Spiecker DB,Grass G,et al.Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma.Histopathology 2001;39:597-602.
[115]Chen BQ,Yang YM,Gao YH et al.Inhibitory effects of c9,t11-conjugated linoleic acid on invasion of human gastric carcinoma cell line SGC-7901.World J Gastroenterol.2003 Sep;9(9):1909-14.
[116]刘 龙,许 玲,孙大志。TIMP2与胃癌中医证型关系的研究。山东中医药大学学报,2007,28(6):424-426.
[2]危北海.慢性萎缩性胃炎的临床研究.陕西中医,1987,8(7):296.
[3]周惠萌,范欣敏.上消化道疾病9910例胃镜检查结果分析.中国中西医结合消化杂志,2003,11(3):167-168.
[4]孟静岩主编.慢性萎缩性胃炎.北京:中国医药科技出版社,2003(8):42.
[5]王永炎主编.中西内科学.上海科技出版社,2002:169.
[6]张聪,陈明.自拟舒胃汤治疗慢性萎缩性胃炎36例[J].辽宁中医学院学报,2004,6(5):381.
[7]祁宏,耿曙光,许定仁,等.萎胃康治疗慢性萎缩性胃炎的疗效及对血液流变学的影响[J].中国中西医结合急救杂志,2004;11(1):42-44.
[8]王钢,常建国,刘红玉.养阴活血法治疗慢性萎缩性胃炎84例.陕西中医,2004;25(1):4.
[9]代二庆:赵占考,袁红霞,等.善胃Ⅰ-Ⅲ号方治疗慢性萎缩性胃炎胃癌前病变的临床研究.中医药学刊,2004;22(4):606.
[10]赵霞.余绍源教授辨治慢性萎缩性胃炎经验.四川中医,2004,22(4):1.
[11]周建莉.胃复春治疗萎缩性胃炎112例[J].实用中医药杂志,2004;20(6):316.
[12]劳绍贤.慢性萎缩性胃炎的临床研究.陕西中医,1987,8(7):289.
[13]项翠华.慢性萎缩性胃炎的病因病机探讨.新疆中医药,2000,18(3):7.
[14]王汝新,牛华珍.温阳补肾活血法治疗慢性萎缩性胃炎180例观察.实用中医药杂志,2000,16(11):11.
[15]刘启泉,杨翠香,肖彦玲等.慢性萎缩性胃炎的中医病机研究.河北中医,2002,24(6):473-475.
[16]危北海,张万岱,陈治水主编.中西医结合消化病学.北京:人民卫生出版社,2003(5):553.
[17]王金荣,王知佳.中医辨证治疗慢性萎缩性胃炎52例[J].中西医结合学报,2004;2(1):65.
[18]高富贵.慢性萎缩性胃炎中医辨证治疗108例.医学理论与实践,2004;17(8):908-909.
[19]张宁.辨证分型治疗慢性萎缩性胃炎128例[J].湖南中医杂志,2004,20(3):4.
[20]任宏义.辨证论治150例慢性萎缩性胃炎的病理形态血观察.中国中西医结合杂志,1993,13(3):144.
[21]柯莹玲,单兆伟.542例慢性萎缩性胃炎患者中医辨证分型与病因分析.辽宁中医杂志,2006,33(2):161-162.
[22]袁福宁.辨证论治慢性萎缩性胃炎50例.光明中医,2006,21(4):59.
[23]王绪霖,潘从清,孙保存.344例慢性萎缩性胃炎患者的辨证分型分析,1999,14、5(1):90-91.
[24]蒋兴伟.李任先教授治疗胃病经验.新中医,1997;29(3):10-11.
[25]刘西峰,白丽萍,米新.辨证治疗慢性萎缩性胃炎96例.陕西中医2004,25(1):8.
[26]魏道祥.辨证分型治疗慢性萎缩性胃炎1276例.山东中医杂志,2003,22(11):673-674.
[27]吴治恒,杨玲,段其昌.和胃调气养血汤加减治疗萎缩性胃炎临床观察.中国民族民间医药杂志,2006,78:38-40.
[28]陈一斌.益胃方治疗慢性萎缩性胃炎60例.河南中医,2006,26(3):34-35.
[29]邓照华.益气健脾汤治疗慢性萎缩性胃炎33例.中国中西医结合消化杂志,2006,14(2):133-134.
[30]潘星宇,王小宁.资生丸治疗慢性萎缩性胃炎110例体会.CJTCM Feb.2006 Vol.18 No.1:68.
[31]李小兵,周红霞.愈胃颗粒治疗慢性萎缩性胃炎128例临床观察. 河南中医,2004,24(3):35.
[32]郑于星.胃炎宁胶囊治疗萎缩性胃炎·临床观察。 Strait Pharmaceutical Journal Vol 19 No.4-2007,83-84.
[33]陈德成,吴旭.穴位注射治疗慢性萎缩性胃炎疗效观察.中国乡村医生杂志,2000年第八期40.
[34]谭奇纹.针刺夹脊穴治疗慢性萎缩性胃炎临床研究.中国针灸,2000年第3期331.
[35]谢文松.药灸并用治疗慢性萎缩性胃炎46例.河北中医,2000第22卷619.
[36]Gao X,Yuan J,Li H,Ren S.Clinical research on acupuncture and moxibustion treatment of chronic atrophic gastritis.J Tradit Chin Med,2007 3un;27(2):87-91.
[37]Gao X,Rao H,Wang Y,Meng D,Wei Y.Protectiveaction of acupuncture and moxibustion on gastric mucosa in model rats with chronic atrophic gastritis.J Tradit Chin Med,2005 Mar;25(1):66-9.
[38]李伟,陈颖莉,杨铭等.胃乐优对胃粘膜损伤的保护作用.中药药理。与临床,1995,11(1):391.
[39]霍本运,许嘉民,王钡礼。胃康泰的药理作用.中成药,1995,13(3):301.
[40]邓兰琼,崔世高,刘喜明,等.柴胡桂枝汤对大鼠胃粘膜保护作用的实验研究.中国中西医结合脾胃杂志,1998,6(3):1641.
[41]徐州,周德瑞,段国勋等.中药对幽门螺杆菌抑制作用的实验研究.中国医药学报,1993;8(5):25-26.
[42]王绪霖,缴稳玲,吕宗舜.抑制幽门螺杆菌中药的初步筛选.中国中西医结合杂志,1994:9(14):534.
[43]苟奎斌,王荣华,孙丽华.中药对幽门螺杆菌的抑菌试验.中国药学杂志,1994;29(9):554.
[44]徐艺,叶柏,单兆伟等.中草药单味与复方对幽门螺杆菌抑菌作用研究.中国中西医结合脾胃志,2000;5(8):292-293.
[45]冀爱英,赵文霞,王智慧等.夏连抑幽胶囊治疗幽门螺杆菌感染性 胃炎的临床及实验研究.中国中西医结合杂志,1999;19(10):595-598.
[46]李振彬,万建喜.和平散对消炎痛致大鼠胃粘膜损伤的保护作用.中国医师杂志,2002;4(10):1108.
[47]张大振,万建喜.胃痛灵汤对胃粘膜保护作用的时间节律研究.河北中医,2002;24(12):956.
[48]王晶,侯家玉,刘衡宽等.胃舒颗粒对胃粘膜保护作用的实验研究.北京中医药大学学报,1999;22(2):59-62.
[49]洪缨,孟紫芊,侯家玉等.小柴胡汤、香砂六君子汤对胃粘膜保护作用的实验研究.北京中医药大学学报,1994;17(5):57-59.
[50].王汝俊,傅定中,邵庭萌.补中益气汤的药理作用研究——抗胃粘膜损伤作用与机理.中药药理与临床,1993(2):5-7.
[51]洪缨,侯家玉,朱洪滨等.小柴胡汤及香砂六君子汤对胃粘液-碳酸氢盐屏障功能影响的实验研究.中药药理与临床,1994;(6):3-5.
[52]刘良,王建华,侯宁等.党参及其有效成分抗胃粘膜损伤作用与机制研究——党参提取物Ⅶ～Ⅱ对胃组织内前列腺素含量的影响.中药药理与临床,1990;6(3):9-11.
[53]李桂,蒋福斌,王建增等.胃康胶囊对消炎痛诱导大鼠胃粘膜损伤血液中相关细胞因子含量的影响.中国中西医结合消化杂志,2003;11(1):33-35.
[54]周兰,孙桂华,宋鸿.中药养胃散对消炎痛损伤的大白鼠胃粘膜的保护作用.广州医药,2001;32(6):9-10.
[55]王长洪,王艳红,周莹等.中药对胃粘膜合成前列腺素的临床及实验研究.中国中西医结合杂志,1994;14(9):528-530.
[56]王付,尚炽昌,梁华龙等.加味黄连汤对大鼠实验性胃粘膜损伤的影响及病理组织学改变.中国中医药信息杂志,2000;7(3):34-35.
[57]徐颖,张祖志,万正清,等.半夏泻心汤对应激性胃粘膜损伤大鼠血管活性肠肽含量的影响.中医药临床杂志,2004;16(2):97.
[58]程村贵,洪洁,王钦茂等.胃泰胶囊的临床药效学研究.医学信息,2002;15(1):71.
[59]姚永莉,宋于刚,张万岱.四君子汤治疗实验脾虚证对胃肠黏膜细 胞增殖动力学的影响.世界华人消化杂志,1999;7:550.
[60]张永锋,王建华,王汝俊.补中益气汤的药理作用研究——抗胃黏膜损伤机理探讨.中药药理与临床,1992;8:1-3.
[61]向爱民,周德端,徐州等.香砂六君合剂对大鼠胃黏膜屏障的保护作用.世界华人消化杂志,1999;7:600.
[62]谢海青,尹昌金,熊磊.香砂六君子汤抗大鼠胃粘膜损伤并脾气虚症实验研究.云南中医学院学报,1992;15(3):15-17.
[63]Namekata T,Miki K,Kimmey M,Fritsche T,Hughes D,Moore D,Suzuki K.Chronic atrophic gastritis and Helicobacter pylori infection among Japanese Americans in Seattle.Am J Epidemiol,2000 Apr 15;151(8):820-30.
[64]Weck MN,Brenner H.Association of Helicobacter pylori infection with chronic atrophic gastritis:Meta-analyses according to type of disease definition.Int J Cancer.2008 Aug 15;123(4):874-81.
[65]Brenner H,Rothenbacher D,Weck MN.Epidemiologic findings on serologically defined chronic atrophic gastritis strongly depend on the choice of the cutoff-value.Int J Cancer,2007 Dec 15;121(12):2782-6.
[66]Weck MN,Stegmaier C,Rothenbacher D,Brenner H.Epidemiology of chronic atrophic gastritis:population-based study among 9444 older adults from Germany.Aliment Pharmacol Ther,2007 Sep 15;26(6):879-87.
[67]马汴梁主编.食管胃肠病中西医结合诊治.北京:人民卫生出版社,2003(8)122-125.
[68]Warren JR and Marshall BJ.Unidentified curved bacillion gastric epithelium active chronic gastritis.Lancet,1983,I:1273-1275.
[69]Kuipers EJ,Uyterlinde AM,Pena AS,et al.Long term sequelae of Helicobacter pylori gastritis.Lancet,1995,345:1525-1528.
[70]Keates AC,Tummala S,Peek RM Jr,Csizmadia E,Kunzli B,Becker K,Correa P,Romero-Gallo J,Piazuelo MB,Sheth S,Kelly CP,Robson SC, Keates S.Helicobacter pylori infection stimulates plasminogen activator inhibitor 1 production by gastric epithelial cells.Infect Immun.2008 Sep;76(9):3992-9.Epub 2008 Jun 2.
[71]Lee YC,Lin JT,Chen TH,Wu MS.Is Eradication of Helicobacter pylori the Feasible Way to Prevent Gastric Cancer? New Evidence and Progress,but Still a Long Way to Go.J Formos Med Assoc.2008Aug;107(8):591-9.
[72]Goldstein NS,Lewin KJ.Gastric epithelial dysplasia and adenoma:historical review and histological criteria for grading.Hum Pathol,1997;28(2):127-133.
[73]Mclord JM.The superoxide free radical:Its biochemistry and pathophysiology.Surgery,1983;9:412-416.
[74]Parks D.Oxygen radicals:mediators of gastrointestinal pathophysiology.Gut,1989;30:293-294.
[75]陈瑗,周玫.自由基医学.第1版.北京:人民军医出版社,1991:4-7.
[76]De Flora S.Antioxidant activity and other mechanisms of thiols involved in chemoprevention of mutation and cancer.Ann J Med,1991;91(Suppl 3C):122-130.
[77]Sandy MS,Dimoute D,Smith MJ.Relationships between intracellular vitamin E,lipid peroxidation and chemical toxicity in hepatocytes.Tokicol Appl Pharmacol,1988;93(1):288-297.
[78]Prise KM,Davies S,Stratford MRL,Michael BD.The role of non protein salphydryls in determining the chemical repair rats of free radical precursors of DNA damage and cell killing in Chinese hamster V 79 cells.Int J Radiat Biol,1992;62(3):297-306.
[79]张玉.慢性萎缩性胃炎胃粘膜血流量的研究.中华消化内镜杂志,1997,14(2):101.
[80]张维颖.慢性萎缩性胃炎患者血液流性学及甲襞微循环变化的研究观察150例微循环杂志.1997,7(1):40.
[81]张旭晨,赵凤志,宋崇顺,等.消痞灵冲剂对实验性胃癌前期病变大鼠血液流变学的影响。新消化病学杂志,1996,4:208-210.
[82]Owen RJ,Hurtado A,Banatvala N,Abdi Y,Davies GR,Feldman R,Hardie JM.Conservation of cytotoxin-associated(cagA) gene of Helicobacter pylori and investigaion of association with vacuolating cytotoxin activity and gastroduodenal disease.FEMS Immun Med Microbiol,1994;9:307-316.
[83]Xiang Z,Censini S,Bayeli PF,et al.Analysis of expression of Cag A and VacA virulence factors in strains of Helicobacterpylori that clinical isolate scan be divided into major types and that Cag A is not necessary for expression of the vacuolating cytotoxin.Infect Immun,1995,63(1):94 98.
[84]Peek RM Jr,MossSF,Tham KT,Perez-Perez GI,Wang S,Miller GG,Atherton JC,Holt PR,Blaser MJ.Helicobacter pylori cagA+strains and dissociation of gastric epithelial cell proliferation from apoptosis.J Natl Cancer Inst,1997;89:863-868.
[85]Vanderberg FM,Mans MZ,Langenberg W,et al.detection of Campylobacterpylori in stomach tissue by DNA insitu hybridization,J clin Pathol,1989;42:955.
[86]熊碧芳,方向明,刘小红,等.幽门螺杆菌细胞毒素相关基因A 与胃癌发生的临床研究.中国内镜杂志,2001(7):4:43.
[87]Romaozinho JM,Souto P,Rodrigues VL,et al.Seroprevalence of comtibodies to CagA and VacA proteins resus gastric cancer risk,Gut 1996;39(S2):A81.
[88]Giannakis M,Chen SL,Karam SM,Engstrand L,Gordon JI.Helicobacter pylori evolution during progression from chronic atrophic gastritis to gastric cancer and its impact on gastric stem cells.Proc Natl Acad Sci U S A.2008 Mar 18;105(11):4358-63.Epub 2008 Mar.
[89]杨金禄.慢性萎缩性胃炎幽门螺杆菌感染量与一氧化氮、脂质过氧化物的变化.医师进修杂志,1997,20(5):250.
[90]韩梅娇,金晓明,牟海滨,等.慢性萎缩性胃炎与幽门螺杆菌cagA、vacA基因相关性研究.哈尔滨医科大学学报,2003年12月第37卷第6期497.
[91]Won Chang Y,Oh HC,Young Jang J,Hwangbo Y,Won Lee J,Jung Lee H,Ro Joo K,Ho Dong S,Soo Kim S,Jong Kim H,Ho Kim B,Chang R.IL-lbeta and IL-8,matrix metalloproteinase 3,and pepsinogen secretion before and after H.pylori eradication in gastroduodenal phenotypes.Scand J Gastroenterol.2008 May 19:1-10.
[92]Greene J,Wang M,Liu YE,Raymond LA,Rosen C,Shi YE.Molecular cloning and characterization of human tissue inhibitor of metalloproteinase-4.J Biol Chem,1996,271(48):30375-30380.
[93]李平安,于美丽。MMP2、TIMP2与胃癌淋巴结转移关系的探讨。中国医学杂志,2004,2(5):241-243.
[94]钟华,徐灿霞,文锋。MMP2、TIMP2与胃癌淋巴结转移关系的探讨。中国医学杂志,2004,2(5):241-243.
[95]Brew K,Dinakarpandian D,Nagase H.Tissue inhibitors of metalloproteinases:evolution,structure and funtion.Biochem Biophys Acta,2000,1477(1-2):267-283.
[96]Olga F.,Manish Kh.and Bruce R S.Metalloproteinase-2expression correlates with aggressiveness of cutaneous squamous cell carcinomas.Modern Pathology,2004.17:496-502.
[97]He Qing,Chen Jie,Lin Han-liang.Expression of peroxisome proliferator-activated receptor g,E-cadherin and matrix metalloproteinases-2 in gastric carcinoma and lymph node metastases.Chinese Medical Journal,2007,120(17):1498-1504.
[98]Lamoreaux WJ,Fitzgerakd M,Reiner A,et al.Vascular endothelial growthfactor increases releases of gelatinase A and decreases release of tissue inhibition of metalloprotainase by microvascular endothelial cells in vitro[J].Microvas Res,1998,55:29.
[99]栾复新,王孟薇.环氧化酶22和基质金属蛋白酶27在老年胃癌组 织中表达及预后意义.军医进修学院学报.2005,25(6):28-29.
[100]李春启,刘为纹,房殿春.实验动物胃粘膜癌前病变的模型建立,发生机理及其逆转治疗的研究.第三军医大学学报,1994;16:5-9.
[101]杨云,陈小野,郭育芝.劳倦和饥饱失常引起的大鼠脾虚证模型的造型及实验研究.中国医药学报,1989;4:65-67.
[102]陈小野,邹世洁.大鼠CAG证病结合模型的造模方法和思路.实验动物科学与管理,2002(19)3:3538.
[103]Si J,Zhou W,Wu J,Cao Q,Xiang Z,Jiang L,L(u|¨) W,Huang H.Establishment of an animal model of chronic atrophic gast.ritis and a study on the factors inducing atrophy.Chin Med J(Engl).2001Dec;114(12):1323-5.
[104]Lee A.A small animal model of human helicobat pylori actine chronic gastritis.GastroenterologY,1990,99:1315.
[105]Fox J G.Helico bacter mustelae-associated gastritis in fernes:ananimal model of helicobacter pylori gastritis in humans.Gastroenterology,1990,99:352.
[106]朱方石.中医药对萎缩性胃炎动物模型研究进展与评述.上海中医药大学学报,2003,17(3):61-64.
[107]赵凤志.人鼠实验性慢性萎缩性胃炎形态研究.北京中医学院学术资料汇编,1989.79.
[108]高碧珍,黄爱民,李灿东,等.不同证候胃炎模型血生化指标的实验研究.福建中医学院学报,2005,15(1):30-32.
[109]Iacopini F,Consolazio A,Bosco D.Oxidative damage of the gastric mucosa in Helicobacter pylori positive chronic atrophic and nonatrophic gastritis,before and after eradication[J].Helicobacter,2003,8(5):503-12.
[110]Sasazuki S,Hayashi T,Nakachi K,Sasaki S,Tsubono Y,Okubo S,Hayashi M,Tsugane S.Protective effect of vitamin C on oxidative stress:a randomized controlled trial[J].Int J Vitam Nutr Res,2008,78(3):121-8.
[111]梁实,月中瘤坏死的另一面,促进某些白血病细胞生长作用,国外医学肿瘤学分册1994,21(6):334。
[112]骆和生,罗鼎辉,主编.免疫中药学.北京:北京医科大学,中国协和医科大学联合出版社出版,1990:97-99.
[113]杨贵贞,等.甘草多糖的体内外免疫效应.中西医结合杂志1988,(基础理论研究特辑),107.
[114]Monig SP,Baldus SE,Hennecken JK,Spiecker DB,Spiecker DB,Grass G,et al.Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma.Histopathology 2001;39:597-602.
[115]Chen BQ,Yang YM,Gao YH et al.Inhibitory effects of c9,t11-conjugated linoleic acid on invasion of human gastric carcinoma cell line SGC-7901.World J Gastroenterol.2003 Sep;9(9):1909-14.
[116]刘 龙,许 玲,孙大志。TIMP2与胃癌中医证型关系的研究。山东中医药大学学报,2007,28(6):424-426.